|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||25.88 - 28.80|
|52 Week Range||24.00 - 51.95|
|Beta (5Y Monthly)||1.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 17, 2021 - May 21, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||67.00|
ABINGDON, OXFORDSHIRE / ACCESSWIRE / September 6, 2021 / Midatech Pharma PLC (AIM:MTPH)(Nasdaq:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it will release its interim results for the six months ended 30 June 2021 at 7.00 am BST on Friday 17 September 2021.
Midatech Pharma PLC ('Midatech' or the 'Company') Midatech Strengthens Management Team with Appointment of Dr. Dmitry Zamoryakhin as Chief Scientific OfficerABINGDON, OXFORDSHIRE / ACCESSWIRE / July 12, 2021 / Midatech Pharma PLC (AIM:MTPH; Nasdaq:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces the appointment of Dr.
Midatech Pharma plc (NASDAQ: MTP) has raised £10 million from equity placing to fund its product development pipeline. Approximately 35 million new shares in the Company were issued at 28.5p each, a 12% discount on Monday's closing price. Considering available cash resources and the expected net proceeds, the Company expects sufficient cash resources to fund operations into Q1 of 2023. The proceeds will be used to develop its Q-Sphera technology following the success with the exemplar mAb disclo